Can an updated COVID-19 vaccine keep up with the virus?
NCT ID NCT07730450
First seen Jul 28, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This trial is testing an updated version of the BNT162b2 COVID-19 vaccine in healthy adults aged 18 to 64. Participants will receive either the updated COVID-19 vaccine or a Tdap vaccine (for tetanus, diphtheria, and whooping cough) to compare safety and measure spike protein levels in the blood. The study aims to see how well the updated vaccine works and whether it is safe for seasonal use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an updated RNA-based COVID-19 vaccine (BNT162b2) targeting a SARS-CoV-2 variant
- What this could lead to
- If successful, this could support the use of updated COVID-19 vaccines for seasonal protection in healthy adults.
- What could go wrong
- This is a phase 4 safety study with only 200 participants, so it may not detect rare side effects or fully predict real-world effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 VACCINES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Diablo Clinical Research, LLC dba Flourish Research
RECRUITINGWalnut Creek, California, 94598, United States
-
Duke Vaccine and Trials Unit
RECRUITINGDurham, North Carolina, 27703, United States
-
East-West Medical Research Institute
RECRUITINGHonolulu, Hawaii, 96814, United States
-
J. Lewis Research, Inc. / Foothill Family Clinic
RECRUITINGSalt Lake City, Utah, 84109, United States
-
Palm Springs Community Health Center
RECRUITINGMiami Lakes, Florida, 33014, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Michigan study tests community-led strategies to boost COVID-19 shots
- New Self-Amplifying RNA vaccine shows promise in massive COVID-19 trial
- Nearly 20 million people studied: does the COVID vaccine still hold up?
- Massive data dive to measure Real-World power of updated COVID shots
- New study aims to shield vulnerable groups from COVID-19